Rapid Release Testing Starts With Faster Contaminant Detection

By Gary Sommerville Ph.D., Principal Scientist, NGS, Technical Services

Traditional, culture-based sterility testing creates significant operational bottlenecks for time-sensitive cell and gene therapies, often taking weeks to deliver results and delaying critical treatment for patients. Transitioning to rapid, sequencing-based analytics transforms contaminant detection into a streamlined, high-throughput process. By leveraging broad-spectrum molecular detection, drug developers can rapidly identify adventitious agents and micro-organisms with exceptional precision early in the production cycle. This shift drastically shortens release testing timelines, reduces expensive batch rejection risks, and accelerates product release without compromising safety. Modernizing contamination testing through scalable genomic workflows safeguards product integrity and establishes a robust quality foundation across the entire manufacturing lifecycle.

Explore how rapid sequencing-based contaminant detection transforms batch release timelines and protects therapy quality.